疏肝益肾方剂对小鼠子宫内膜癌移植瘤的影响及其机制的研究  

Shuganyishen's Effect on Transplantable Endometrial Carcinoma in Mice and its Mechanism

作　　者：范秀华[1] 卢雯平[2] 李晓[1] 李向英[2] 胡建秀[1] 李爱民[1] 

机构地区：[1]河北医科大学第二医院妇产科,石家庄050017 [2]中国医学科学院广安门医院肿瘤科,北京100053

出　　处：《中国实验方剂学杂志》2010年第10期175-178,共4页Chinese Journal of Experimental Traditional Medical Formulae

摘　　要：目的:以顺铂为对照药,研究中药疏肝益肾方剂对子宫内膜癌Ishikawa细胞的小鼠模型的抑瘤效果。方法:用免疫组织化学方法检测对照组、中药组、顺铂组和联合组小鼠荷瘤标本中ERα,ERβ及PR的表达。结果:ERα蛋白在对照组表达最高,依次为顺铂组、中药组、联合组,ERβ蛋白在中药组表达最高,依次为联合组、对照组、顺铂组,PR蛋白在联合组表达最高,依次为中药组、顺铂组、对照组。结论:疏肝益肾方剂对子宫内膜癌有一定的抑制作用,但更重要的是联合使用化疗药物后既可以取得好的抑瘤效果,又针对性的对ERα起到抑制作用,提高PR的表达,并且几乎不影响ERβ的表达。故该方剂联合常规化疗药后可以克服常规化疗药物对雌激素的抑制作用。Objective：Compared with cisplatin,study on the inhibitory effect of shuganyishen on Ishikawa cells on mouse model. Method：Immunohistochemical method was used to detect the expressions of ERα,ERβ and PR in the transplantable endometrial carcinoma of mice in control group,shuganyishen group,cisplatin group and shuganyishen-cisplatin group. Result：ERα protein expressed highest in control group,and in cisplatin group,shuganyishen group and shuganyishen-cisplatin group in order. ERβ protein expressed highest in shuganyishen group,and in shuganyishen-cisplatin group,control group and cisplatin group in order. PR protein expressed highest in shuganyishen-cisplatin group,and in shuganyishen group,cisplatin group and control group in order. Conclusion：Shuganyishen has a certain effect on inhibiting endometrial carcinoma. Furthermore,shuganyishen combined with conventional chemotherapy is good to inhibit tumor and ERα and improve the expression of PR,without affecting ERβ. So the combined prescription can solve the problem of estrogen inhibition caused by using chemotherapy alone.

关 键 词：子宫内膜癌 雌激素受体亚型 孕激素受体 中药疏肝益肾方剂 顺铂 ISHIKAWA细胞 动物模型 

分 类 号：R285.5[医药卫生—中药学]